Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 4, 2012, Pages 441-447

  Sicras Mainar, A ^a   Planas Comes, A ^b   Frias Garrido, X ^a   Navarro Artieda, R ^c   De Salas Cansado, M ^d   Rejas Gutierrez J ^e  

^a Badalona Serveis Assistencials SA   (Spain)

^b Badalona Serveis Assistencials SA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Health Outcomes Research Unit   (Spain)

^e PFIZER INC   (United States)

Author keywords

elderly; guidelines; major cardiovascular event; recurrence; secondary prevention; statins; stroke

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; AGED; AGING; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; RECURRENT DISEASE; RETROSPECTIVE STUDY; STROKE; SURVIVAL;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MEDITERRANEAN REGION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK; SPAIN; STROKE; SURVIVAL RATE; TIME FACTORS;

EID: 84863468040     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01318.x     Document Type: Article

References (31)

1. Truelsen T, Ekman M, Boysen G,. Cost of stroke in Europe. Eur J Neurol, 2005; 12 (Suppl 1): S78-S84.
2. Hervás-Angulo A, Cabesés-Hita JM, Forcén-Alonso T,. Costes del ictus desde la perspectiva social. Enfoque de incidencia retrospectiva con seguimiento a tres años. Rev Neurol, 2006; 43: 518-525. (Pubitemid 47573993)
3. Fernández de Bobadilla J, Sicras-Mainar A, Navarro-Artieda R, et al. Estimación de la prevalencia, incidencia, comorbilidades y costes directos asociados en pacientes que demandan atención por ictus en un ámbito poblacional español. Rev Neurol, 2008; 46: 397-405. (Pubitemid 351767908)
4. Truelsen T, Piechowski-Józwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G,. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol, 2006; 13: 81-98.
5. Hankey GJ,. Secondary prevention of recurrent stroke. Stroke, 2005; 36: 218-221. (Pubitemid 40170788)
6. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MSV,. Recurrent stroke and cardiac risks after first ischemic stroke. The Northern Manhattan Study. Neurology, 2006; 66: 641-646. (Pubitemid 43739815)
7. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. N Engl J Med, 2006; 355: 549-559.
8. Amarenco P, Goldstein LB, Sillesen H, et al. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease. Findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke, 2010; 41: 426-430.
9. Goldstein LB, Amarenco P, Zivin J, et al. Stroke prevention by aggressive reduction in cholesterol levels investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2009; 40: 3526-3531.
10. Welch KM,. Review of the SPARCL trial and its subanalyses. Curr Atheroscler Rep, 2009; 11: 315-321.
11. Rodríguez-Yáñez M, Dávalos A, Castillo J,. Withdrawal from statins: implications for secondary stroke prevention and acute treatment. Int J Stroke, 2008; 3: 85-87. (Pubitemid 351566840)
12. Fitchett DH, Goodman SG, Langer A,. Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Can J Cardiol, 2008; 24: 705-708.
13. Anónimo. Guidelines for ATC classification. Oslo: Nordic Collaborating Centre for Drug Statistics Methodology, 1991.
14. Lobos J, Royo-Bordonada M, Brotons C, et al. European guidelines on cardiovascular disease prevention in clinical practice. Spanish Adaptation of the CEIPC 2008. Neurologia, 2009; 24: 465-484.
15. Cooper A, Nherera L, Calvert N, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating centre for Primary Care and Royal College of general Practitioners, 2008.
16. Mar J, Begiristain JM, Arrazola A,. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovascular Diseases, 2005; 20: 193-200. (Pubitemid 41254181)
17. Rothwell PM,. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet, 2001; 357: 1612-1616. (Pubitemid 32488832)
18. Banegas JR, Rodríguez-Artalejo F, Graciani A, Villar F, Herruzo R,. Mortality attributable to cardiovascular risk factors in Spain. Eur J Clin Nutr, 2003; 57 (Suppl 1): S18-S21. (Pubitemid 37121022)
19. Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology, 2009; 72: 688-694.
20. Athyros VG, Kakafika AI, Tziomalos K, Papageorgiou AA, Karagiannis A,. Statins for the prevention of first or recurrent stroke. Curr Vasc Pharmacol, 2008; 6: 124-133.
21. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2007; 38: 3198-3204. (Pubitemid 350175737)
22. Bybee KA, Lee JH, O'Keefe JH,. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Curr Med Res Opin, 2008; 24: 1217-1229. (Pubitemid 351579181)
23. Doggrell SA,. Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Rev Recent Clin Trials, 2006; 1: 143-153.
24. Sanossian N, Ovbiagele B,. Drug insight: translating evidence on statin therapy into clinical benefits. Nat Clin Pract Neurol, 2008; 4: 43-49.
25. Fernández de Bobadilla J, Moreno R, Fernández C, Martínez A, Sánchez-Maestre C, Ezpeleta-Echevarri D,. Efecto del tratamiento intensivo con atorvastatina frente a dosis estándar de estatinas en el riesgo de ictus de pacientes con enfermedad coronaria previa. Metaanálisis de cinco ensayos aleatorizados con 25.709 pacientes. Rev Neurol, 2009; 48: 561-565.
26. Singh V, Deedwania P,. Expanding roles for atorvastatin. Drugs Today (Barc), 2008; 44: 455-471.
27. Gaspardone A, Arca M,. Atorvastatin: its clinical role in cerebrovascular prevention. Drugs, 2007; 67 (Suppl 1): 55-62.
28. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg, 2007; 45: 645-654.
29. Prinz V, Endres M,. Statins and stroke: prevention and beyond. Curr Opin Neurol, 2011; 24: 75-80.
30. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet, 2011; 378: 1231-1243.
31. Alhusban A, Fagan SC,. Secondary prevention of stroke in the elderly: a review of the evidence. Am J Geriatr Pharmacother, 2011; 9: 143-152.